PINK1 and drug-induced dyskinesia: Limited data support that PINK1 mutation carriers show a transient therapeutic benefit after surgery; however, in the long-term follow-up they developed axial symptoms and dyskinesia and were almost unresponsive to drug therapy and neurostimulation.